Paclitaxel / Tyro3 Cancer Research Results

PacT, Paclitaxel: Click to Expand ⟱

Features:

Paclitaxel (brand name Taxol) is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. Administered by intravenous injection.
Derived from a natural product, Taxol (from Pacific Yew Tree).
Paclitaxel is a drug (chemotherapy; a taxane). Its dominant anticancer mechanism is microtubule stabilization, which disrupts normal mitosis and drives mitotic arrest/stress signaling that can culminate in apoptosis.

Paclitaxel – Cancer Pathway Matrix

Rank	Pathway / Axis	Cancer / Tumor Context	Normal Tissue Context	TSF	Primary Effect	Notes / Interpretation
1	Microtubule stabilization → Mitotic arrest	Mitotic progression ↓; spindle dynamics impaired; cell division blocked	Proliferating normal cells affected	R, G	Core cytotoxic mechanism	Binds β-tubulin and stabilizes microtubules, preventing normal depolymerization required for mitosis.
2	Spindle assembly checkpoint activation	Prolonged mitotic arrest → mitotic catastrophe or apoptosis	Checkpoint stress in dividing tissues	R, G	Mitotic stress execution	Cell fate depends on whether arrest resolves via apoptosis or mitotic slippage.
3	Intrinsic apoptosis (mitochondrial pathway)	Caspase activation ↑; BAX/mitochondrial signaling engaged (context)	Limited unless stressed	G	Cell death execution	Often downstream of prolonged mitotic stress and mitochondrial perturbation.
4	ROS generation (secondary)	ROS ↑ (context-dependent); oxidative stress amplification	Oxidative stress possible in sensitive tissues	R, G	Stress amplifier	ROS rise appears secondary to mitotic and mitochondrial dysfunction; may enhance apoptosis.
5	Nrf2 antioxidant response (adaptive)	Nrf2 ↑ in some tumors; antioxidant buffering ↑; resistance potential	Protective antioxidant signaling	G	Adaptive resistance axis	Not a direct paclitaxel target; elevated Nrf2 may reduce drug sensitivity.
6	Drug resistance mechanisms	P-glycoprotein (MDR1) ↑; β-tubulin alterations; survival rewiring	—	G	Treatment failure driver	Efflux pumps and tubulin adaptations are major clinical resistance mechanisms.
7	Myelosuppression	—	Neutropenia risk ↑	G	Dose-limiting toxicity	Bone marrow suppression is a primary clinical constraint.
8	Peripheral neuropathy	—	Sensory neuropathy risk ↑	G	Dose-limiting toxicity	Likely related to microtubule disruption in axonal transport.

Time-Scale Flag (TSF):
P = 0–30 min (drug binding begins)
R = 30 min–3 hr (mitotic stress signaling, ROS changes)
G = >3 hr (apoptosis, resistance adaptation, tissue toxicities)

Tyro3, Tyro3: Click to Expand ⟱

Source:

Type: receptor tyrosine kinase

Tyro3 is a receptor tyrosine kinase that plays a crucial role in the regulation of cell growth, survival, and migration. Tyro3 is a member of the TAM (Tyro3, Axl, and Mer) family of receptors, which are involved in the regulation of various cellular processes, including cell growth, survival, and migration.

Scientific Papers found: Click to Expand⟱

577-

Api,

PacT,

Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells

in-vitro,

Ovarian,

SKOV3

40uM

p‑Akt↓, Bcl-xL↓, Bcl-2↓, AXL↓, Tyro3↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Cell Death ⓘ

p‑Akt↓, 1, Bcl-2↓, 1, Bcl-xL↓, 1,

Migration ⓘ

AXL↓, 1, Tyro3↓, 1,
Total Targets: 5

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: Tyro3, Tyro3

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells